DK3404024T3 - Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser - Google Patents
Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser Download PDFInfo
- Publication number
- DK3404024T3 DK3404024T3 DK17738201.7T DK17738201T DK3404024T3 DK 3404024 T3 DK3404024 T3 DK 3404024T3 DK 17738201 T DK17738201 T DK 17738201T DK 3404024 T3 DK3404024 T3 DK 3404024T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- pharmaceutical composition
- quinazoline derivative
- quinazoline
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610023840 | 2016-01-14 | ||
| PCT/CN2017/071147 WO2017121388A1 (zh) | 2016-01-14 | 2017-01-13 | 喹唑啉酮衍生物、其制备方法、药物组合物及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3404024T3 true DK3404024T3 (da) | 2021-01-11 |
Family
ID=59310818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17738201.7T DK3404024T3 (da) | 2016-01-14 | 2017-01-13 | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11001566B2 (da) |
| EP (1) | EP3404024B1 (da) |
| JP (1) | JP6930748B2 (da) |
| KR (1) | KR102331013B1 (da) |
| CN (1) | CN108473461B (da) |
| AU (1) | AU2017206382C1 (da) |
| CA (1) | CA3011254C (da) |
| DK (1) | DK3404024T3 (da) |
| ES (1) | ES2839523T3 (da) |
| HK (1) | HK1255062A1 (da) |
| NZ (1) | NZ744387A (da) |
| PL (1) | PL3404024T3 (da) |
| RU (1) | RU2730500C2 (da) |
| WO (1) | WO2017121388A1 (da) |
| ZA (1) | ZA201804692B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2730500C2 (ru) * | 2016-01-14 | 2020-08-24 | Канпу Биофармасьютикалз, Лтд | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения |
| HRP20231199T1 (hr) | 2018-04-23 | 2024-01-19 | Celgene Corporation | Supstituirani spojevi 4-aminoizoindolin-1,3-diona i njihova upotreba za liječenje limfoma |
| CN108654689B (zh) * | 2018-06-22 | 2021-08-03 | 南京大学 | 一种低共熔非腐蚀酸性催化剂、制备方法及其用途 |
| WO2020210630A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
| WO2021168314A1 (en) * | 2020-02-21 | 2021-08-26 | Plexium, Inc. | Quinazolinone compounds and related compounds |
| US20230303539A1 (en) * | 2020-08-14 | 2023-09-28 | Shanghaitech University | Immunoregulatory compound and antitumor application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE026827T2 (en) * | 2006-09-26 | 2016-07-28 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| MY157495A (en) | 2007-09-26 | 2016-06-15 | Celgene Corp | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| BR112013023277A2 (pt) * | 2011-03-11 | 2017-06-27 | Celgene Corp | métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona |
| JP2015531776A (ja) * | 2012-09-04 | 2015-11-05 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
| AU2014205043B2 (en) * | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| WO2014152833A1 (en) * | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| RU2730500C2 (ru) * | 2016-01-14 | 2020-08-24 | Канпу Биофармасьютикалз, Лтд | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения |
-
2017
- 2017-01-13 RU RU2018129344A patent/RU2730500C2/ru active
- 2017-01-13 WO PCT/CN2017/071147 patent/WO2017121388A1/zh active Application Filing
- 2017-01-13 KR KR1020187022763A patent/KR102331013B1/ko active IP Right Grant
- 2017-01-13 AU AU2017206382A patent/AU2017206382C1/en active Active
- 2017-01-13 JP JP2018555808A patent/JP6930748B2/ja active Active
- 2017-01-13 CN CN201780006458.XA patent/CN108473461B/zh active Active
- 2017-01-13 ES ES17738201T patent/ES2839523T3/es active Active
- 2017-01-13 US US16/069,026 patent/US11001566B2/en active Active
- 2017-01-13 DK DK17738201.7T patent/DK3404024T3/da active
- 2017-01-13 PL PL17738201T patent/PL3404024T3/pl unknown
- 2017-01-13 NZ NZ744387A patent/NZ744387A/en unknown
- 2017-01-13 CA CA3011254A patent/CA3011254C/en active Active
- 2017-01-13 EP EP17738201.7A patent/EP3404024B1/en active Active
-
2018
- 2018-07-13 ZA ZA2018/04692A patent/ZA201804692B/en unknown
- 2018-11-07 HK HK18114190.9A patent/HK1255062A1/zh unknown
-
2021
- 2021-03-24 US US17/211,203 patent/US11702399B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102331013B1 (ko) | 2021-11-26 |
| AU2017206382A1 (en) | 2018-08-02 |
| RU2018129344A3 (da) | 2020-02-21 |
| US11702399B2 (en) | 2023-07-18 |
| PL3404024T3 (pl) | 2021-04-19 |
| JP6930748B2 (ja) | 2021-09-01 |
| JP2019501977A (ja) | 2019-01-24 |
| HK1255062A1 (zh) | 2019-08-02 |
| NZ744387A (en) | 2021-07-30 |
| RU2018129344A (ru) | 2020-02-17 |
| AU2017206382B2 (en) | 2020-08-20 |
| RU2730500C2 (ru) | 2020-08-24 |
| CN108473461B (zh) | 2021-06-15 |
| WO2017121388A1 (zh) | 2017-07-20 |
| US20210206743A1 (en) | 2021-07-08 |
| EP3404024B1 (en) | 2020-11-18 |
| US20200039950A1 (en) | 2020-02-06 |
| EP3404024A4 (en) | 2019-07-31 |
| EP3404024A1 (en) | 2018-11-21 |
| KR20180100211A (ko) | 2018-09-07 |
| US11001566B2 (en) | 2021-05-11 |
| ZA201804692B (en) | 2020-03-25 |
| CA3011254C (en) | 2022-03-15 |
| AU2017206382C1 (en) | 2020-12-24 |
| ES2839523T3 (es) | 2021-07-05 |
| CA3011254A1 (en) | 2017-07-20 |
| CN108473461A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3453707T3 (da) | Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3486242T3 (da) | Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf | |
| DK3312177T3 (da) | Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme | |
| DK3354649T3 (da) | Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler | |
| DK3559000T3 (da) | Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf | |
| DK3214081T3 (da) | Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf | |
| DK3510157T3 (da) | Pd-1-homing-endonucleasevarianter, sammensætninger og fremgangsmåder til anvendelse | |
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| DK3313817T3 (da) | Bicycliske derivater, fremgansmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende disse | |
| DK3378859T3 (da) | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3381469T3 (da) | Anti-erbb2 antistoflægemiddelskonjugat og sammensætning deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| DK3153169T3 (da) | Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt | |
| DK3404024T3 (da) | Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3388420T3 (da) | Quinolin-forbindelser, metode til fremstilling deraf og anvendelse deraf som urattransporter-hæmmende lægemiddel | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3409660T3 (da) | Cyklisk aminderivat og farmaceutisk anvendelse deraf | |
| DK3750893T3 (da) | Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3357343T3 (da) | Fedtsammensætning og fremgangsmåde til fremstilling heraf | |
| EP3181553A4 (en) | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | |
| DK3271453T3 (da) | Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3229843T3 (da) | Farmaceutisk sammensætning, præparat og anvendelser deraf |